BUSCANDO EL ORIGEN DEL LIQUEN PLANO !!
LOOKING FOR THE ORIGIN OF LICHEN PLANUS !!
PUBLICADO 2.017 ACTUALIZADO 2.025
EDITORIAL ESPAÑOL
===================
Hola amigos de la red. DERMAGIC de
nuevo con ustedes. En esta nueva revisión sobre el LIQUEN PLANO,
enfermedad descrita hace más de 150 años y que hoy día su tratamiento
sigue siendo todo un reto para los dermatólogos de la nueva
era.
Posteriormente Darier en 1905
describió las características histopatológicas de la
enfermedad.
Después de muchos años el avance de la ciencia a logrado descifrar
numerosos eventos acerca del LIQUEN PLANO, ellos son:
ETIOLOGÍA:
1.- INMUNOMEDIACIÓN
El liquen plano es una enfermedad inflamatoria crónica que hoy dia es
considerada de etiología desconocida, la cual es producida por una
REACCIÓN INMUNITARIA, mediada por linfocitos T citotóxicos que atacan queratinocitos
basales, causando daño y apoptosis en la piel y mucosas,
2.) FACTORES DESENCADENANTES:
Diversos factores pueden actuar como desencadenantes, entre ellos
figuran:
A.- INFECCIONES VIRALES:
siendo el virus de la
hepatitis C
y
hepatitis B
las asociaciones más importantes.
B.- MEDICAMENTOS:
-
Antihipertensivos: inhibidores de la enzima convertidora de angiotensina
(IECA=Enalapril), y betabloqueadores: metoprolol, atenolol, propranolol,
bisoprolol, carvedilol, labetalol, nebivolol).
- Aantimaláricos (cloroquina e hidroxicloroqiina).
-
Antiinflamatorios NO ESTEROIDEOS (AINES): como el ibuprofeno y naproxeno, y otros.
-Medicamentos para la diabetes tipo2: (sulfonilurea).
- Diureticos: tiazidas.
- Penicilamina (utilizada en enfermedades reumaticas).
Estos son los mas frecuentemente descritos, pero en la experiencia
cotidiana, cualquier medicamento te puede ocasionar un LIQUEN PLANO,
muchas veces encontrado en la literatura como
ERUPCIÓN LIQUENOIDE POR DROGAS,
pero histopatológica y clínicamente se trata de un LIQUEN PLANO.
C.- CONTACTO CON ALÉRGENOS: el contacto con alérgenos dentales como la amalgama, y los
reveladores utilizados en PLACAS RADIOLÓGICAS, y FOTOGRAFÍA.
3.) PREDISPOSICIÓN GENÉTICA:
Existe una asociación comprobada del LIQUEN PLANO con los antígenos de
Histocompatibilidad, con ciertos haplotipos HLA, con las moleculas clase
II,
HLA-DR1, y la
aparición de casos familiares, lo cual demuestra un componente genético en la susceptibilidad a
presentar esta patología.
4.) ENFERMEDADES AUTOINMUNES ASOCIADAS:
El liquen plano suele coexistir con otras enfermedades
autoinmunes, entre las que se describen:
a.-
Alopecia areata.
b.- Colitis ulcerosa.
c.- Lupus
discoide crónico.
d.- reforzando su naturaleza
inmunitaria.
e.- Enfermedad celíaca.
f.-
Dermatomiositis.
g.- Tiroiditis autoinmune (de
Hashimoto).
h.- Liquen escleroso y atrófico.
5.) FACTORES AMBIENTALES Y SISTÉMICOS:
El estrés psicológico, alteraciones en el microbioma (virus bacterias y
hongos que habitan en el cuerpo humano), y sustancias químicas (ya
descritas), también pueden modificar la respuesta inmune y pueden
disparar la aparición de esta patología.
NOTA:
Hasta hoy día no ha sido descrito
NINGÚN ORGANISMO específico, o AGENTE VIVO como causante primario del LIQUEN
PLANO.
CARACTERÍSTICAS CLÍNICAS:
Se caracteriza por lesiones planas, violáceas, brillantes y con
pápulas poligonales que presentan en su superficie unas estrías
blanquecinas denominadas
ESTRÍAS DE WICKHAM
en honor a su descubridor, el prurito o picazón es típicamente
descrito por ciclos (en ocasiones se presenta en ocasiones no se
presenta).
Las lesiones pueden presentarse en cualquier
parte del cuerpo, incluyendo mucosas y anexos como uñas y cuero
cabelludo.
En la mucosa bucal se presentan en el paladar y
la superficie de la lengua como estriaciones blanquecinas, son por lo
general dolorosas, incluyendo la región genital.
Puede
presentarse tanto en masculinos como femeninos, y por lo general en la
edad adulta, pero también se ha descrito en adolescentes y niños.
LA ENFERMEDAD NO ES CONTAGIOSA
LIQUEN PLANO TÓRAX ANTERIOR
TIPOS CLÍNICOS DE LIQUEN PLANO:
-------------------------------------------
1.)
Actínico.
2.) Anular.
3.) Buloso.
4.) Clásico.
5.)
Eritematoso.
6.) Exfoliativo.
7.) Familiar
8.) En
gota.
9.) Hipertrófico.
10.) "invisible"
11.)
Lineal.
12.)uco-membranoso (genital, esófago)
13.) Uñas.
14.)
Oral.
15.) Penfigoide.
16.) Perforante.
17.)
Pigmentoso.
18.) Plano Pilar.
19.) Ulcerativo
20.)
Zosteriforme
El oral tiene 6 tipos: Reticulado, atrófico,
papular, en placa, erosivo y buloso.
ENFERMEDADES ASOCIADAS:
-----------------------------------------------
Se han
descrito numerosas enfermedades asociadas con LIQUEN PLANO entre
ellas:
A.) MALIGNAS:
----------------------
1.)
Cáncer de estómago.
2.) Linfoma.
3.) Neuroblastoma.
4.) Adenoma de la
pituitaria.
5.) Fibrohistiocitoma.
6.) Paraproteinemia
monoclonal por IGA Kappa.
7.) Craneofaringioma
8.)
Malignidad pararenal.
9.) Sarcoma.
B.) ENFERMEDADES GASTROINTESTINALES Y ENDOCRINAS.
----------------------------------------------------------------------------------------------
1.)
Cirrosis biliar primaria.
2.) Hepatitis crónica activa.
3.)
Colitis Ulcerativa.
4.) Diabetes mellitus.
5.)
Anormalidad en el funcionamiento del hígado (enzimas)
C.) ENFERMEDADES AUTOINMUNES:
----------------------------------------------------------
1.)
Alopecia Areata.
2.) Dermatomiositis.
3.) Dermatitis
Herpetiforme.
4.) Tiroiditis de Hashimoto.
5.)
Queratoconjuntivitis seca y xerostomía.
6.) Morfea.
7.)
Miastenia Gravis.
8.) Pénfigo foliáceo.
9.) Pénfigo
Vulgar.
10.) Anemia perniciosa.
11.) Esclerosis
sistémica.
12.) Timoma.
13.) Vitíligo.
También
el LIQUEN PLANO a sido asociado al uso de numerosas drogas y
sustancias:
LIQUEN PLANO BOCA
DROGAS ASOCIADAS CON LIQUEN PLANO :
-------------------------------------------------------------
Numerosas drogas han estado involucradas en la aparición de
LIQUEN PLANO, denominadas LIQUEN PLANO-LIKE reacciones, entre
ellas:
A.) ANTIHIPERTENSIVOS:
Captopril, cloro tiazida, Enalapril, Hidroclorotiazida, Labetolol,
Metildopa, practolol, propanolol, espironolactona.
B.) ANTIBIÓTICOS:
Demaclociclina, Etambutol, Griseofulvina, Ketoconazol, Levamisol,
Acido para-amino-salicílico, estreptomicina, tetraciclina.
C: AINES: (ANTIINFLAMATORIOS NO ESTEROIDEOS:
Naproxeno, Indometacina, Feclofenac, Diflunisal, Flurbiprofen,
Benoxaprofen, Acido acetil salicílico.
D: ANTIMALARICOS:
Cloroquina, Quinacrina, Quinidina, Quinina.
E.) PSICOTROPICOS:
Carbamazepina, Levomepromazina, Metopromazina,
F.) AGENTES REVELADORES DE FILMS:
4-Amino-N-dietil-analina sulfato (TTS), CD2, CD3,
P-isopropilamino-difenilamina (IPPD)
G.) SULFONILUREAS:
Clorpropamida, Tolazamida, Tolbutamida.
H.) MISCELANEOS:
Alopurinol, anfenazole, arsénico, cinarizina, oro, meticran,
Musk ambrette, penicilamina, probenecid, pirimetamina,
mercaptopropionilglicina, piritioxina, Medios de radiocontraste,
trihexifenidil, interferon-alpha-N1
... y probablemente existan otras mas que no están en esta
lista.
Genéticamente se ha establecido una asociación de los antígenos
HLA y EL LIQUEN PLANO, también el STRESS emocional es un factor
desencadenante, el consumo de TABACO también se ha relacionado al
mismo y las infecciones.
LIQUEN PLANO CLÁSICO DEL PIE
ALTERNATIVAS TERAPÉUTICAS:
---------------------------------------------------
Se ha utilizado varias propuestas para el tratamiento del LIQUEN
PLANO, entre ellas destacan:
1.) RETINOIDES: Isotretinoina, Etretinato, Acitretin,
2.)
GRISEOFULVINA.
3.) CICLOSPORINA A.
4.) ANTIBIÓTICOS:
Penicilina, Isoniacida, Aureomicina, Trimetoprim-Sulfametoxazol,
tetraciclina
5.) ANTIPARASITARIOS: Metronidazol, Levamisol.
6.)
DAPSONA y TALIDOMIDA
7.) ANTIMALÁRICOS: cloroquina, hidroxicloroquina, quinina, quinacrina.
8.) RADIOTERAPIA.
9.) ANTIMETABOLITOS: Ciclofosfamida,
metotrexato.
10.) CORTICOSTEROIDES: Clobetasol y acetonido de
triamcinolona.
11.) MEDICACIÓN PSIQUIÁTRICA: Sulpiride.
12.)
AZATIOPRINA.
13.) PUVA: psoralenos mas radiación UVA
14.)
CIRUGÍA.
15.) VIEJAS TERAPIAS INCLUYEN: Mercurio sistémico, Acido
nicotínico, Bismuto, vitaminas, calcio intravenoso, y
arsenicales.
LIQUEN PLANO DE LA LENGUA
NUEVAS ALTERNATIVAS DE TRATAMIENTO:
------------------------------------------------------------
1.) DERIVADOS DE PLAQUETAS E INMUNOSUPRESIÓN.
2.)
glycyrrhizin (LICORICE), HIERBA DE ORIGEN CHINO.
3.)
TACROLIMUS
Y PIMECROLIMUS TÓPICO
4.) HEPARINA (ENOXAPARIN)
5.)
INTERFERON ALFA- 2b
6.) FOTOQUIMIOTERAPIA EXTRACORPOREA.
7.)
MICOFENOLATO DE MOFETIL
8.) AMLEXANOX PASTA FORMULADA AL 5%
9.)
LASER DE DIODO. (Terapia de Laser de bajo nivel)
10.) BARICITINIB (Inhibidor de la Janus Kinasa JAK 1 y 2)
11.) TOFACITINIB ( Inhibidor de la Janus Kinasa JAK 1 y 3)
12.)
RUXOLITINIB (Inhibidor topico de la Janus Kinasa 1 y 2).
13. DEUCRACITINIB (Es un inhibidor selectivo de la tirosina quinasa 2
(TYK2, actualmente en estudio en el Liquen plano).
14. UPACITINIB (Inhibidor de la Janus Kinasa JAK 1).
Quizá una de las cosas mas importantes de esta revisión es LA GRAN
ASOCIACIÓN QUE SE DESCRIBE actualmente ENTRE EL LIQUEN PLANO Y LA
HEPATITIS CRÓNICA C Y B, y la
VACUNACIÓN contra LA MISMA HEPATITIS B, o anormalidades en el funcionamiento hepático.
En base a todos estos hallazgos PODRÍAMOS CLASIFICAR EL LIQUEN
PLANO DENTRO DE 7 VARIANTES, en cuanto a su ORIGEN:
1.) ASOCIADO A ENFERMEDAD HEPÁTICA.
2.) ASOCIADO A OTRAS
ENFERMEDADES NO HEPÁTICAS.
3.) INDUCIDO POR DROGAS Y
CONTAMINANTES.
4.) IDIOPÁTICO.5.) MARCADOR CUTÁNEO DE MALIGNIDAD.
6.) GENÉTICO (HLA
ANTÍGENOS)
7.) ASOCIADO A VACUNACIÓN CONTRA HEPATITIS B
LIQUEN PLANO LINEAL: FRENTE A PUNTA DE NARIZ
Probablemente Erasmus WILSON nunca pensó la gran relación que ha sido
descubierta entre el LIQUEN PLANO y ENFERMEDAD HEPÁTICA o
anormalidades en el funcionamiento HEPÁTICO, y mas aun la aparición de
esta enfermedad después de vacunación contra otra enfermedad
(HEPATITIS B)...
.. En estas 81 referencias los hechos en el adjunto: liquen
plano clásico, lineal, boca y pecho.
Dr. José M. Lapenta.
EDITORIAL ENGLISH
===================
Hello friends of the net. DERMAGIC again with you. In this new review
about the LICHEN PLANUS, disease described more than 150 years ago and
that nowadays their treatment continues being an entire challenge for
the dermatoligist of the new era.
ERASMUS WILSON was the first to use the term LICHEN PLANUS in 1869. The first variant of the disease was described by Kaposi in 1892, calling it Lichen Ruber Pemphigoides ruber pemphigoids, and Frederic Wickham in 1895 described the WHITE STRIATIONS
on the upper surface of the lesions.
Darier later described the histopathological characteristics of the disease
in 1905.
After many years of scientific advancement, numerous factors
have been clarified regarding LICHEN PLANUS. These factors are:
ETIOLOGY:
1. IMMUNOMEDIATION
Lichen planus is a chronic inflammatory disease currently
considered of unknown etiology. It is caused by an
IMMUNE REACTION mediated by cytotoxic T lymphocytes that attack basal keratinocytes,
causing damage and apoptosis in the skin and mucous membranes.
2. TRIGGERING FACTORS:
Several factors can act as triggers, including:
A. VIRAL INFECTIONS:
the hepatitis C and hepatitis B viruses being the most important
associations.
B.- MEDICINES:
- Antihypertensives: angiotensin-converting enzyme
inhibitors (ACE inhibitors = enalapril) and beta-blockers: metoprolol,
atenolol, propranolol, bisoprolol, carvedilol, labetalol,
nebivolol).
- Antimalarials (chloroquine and
hydroxychloroquine).
- Nonsteroidal anti-inflammatory drugs
(NSAIDs): such as ibuprofen and naproxen, among others.
-
Medications for type 2 diabetes: (sulfonylurea).
-
Diuretics: thiazides.
- Penicillamine (used in rheumatic
diseases).
These are the most frequently described, but in
everyday experience, any medication can cause lichen planus. Lichen
planus is often described in the literature as
LICHENOID DRUG ERUPTION, but histopathologically and clinically it is actually lichen
planus.
C. CONTACT WITH ALLERGENS:
Contact with dental allergens such as amalgam, and the developers used
in X-ray films and photography.
3. GENETIC PREDISPOSITION:
There is a proven association of lichen planus with
histocompatibility antigens, certain HLA haplotypes, class II
molecules,
HLA-DR1, and the occurrence of familial cases, which demonstrates a genetic
component in the susceptibility to this disease.
4.) ASSOCIATED AUTOIMMUNE DISEASES:
Lichen planus often coexists with other autoimmune
diseases, including:
a. Alopecia areata.
b.
Ulcerative colitis.
c. Chronic discoid lupus.
d.
Reinforcing its immune nature.
e. Celiac disease.
f.
Dermatomyositis.
g. Autoimmune thyroiditis
(Hashimoto's).
h. Lichen sclerosus et atrophicus.
5.) ENVIRONMENTAL AND SYSTEMIC FACTORS:
Psychological stress, alterations in the microbiome (viruses,
bacteria, and fungi that inhabit the human body), and chemical
substances (already described) can also modify the immune response and
trigger the onset of this pathology.
NOTE:
To date, no SPECIFIC ORGANISM or LIVING AGENT
has been described as the primary cause of lichen planus.
CLINICAL FEATURES:
It is characterized by flat, purplish, shiny lesions with
polygonal papules that have whitish striations on their surface,
called
WICKHAM'S STRIATIONS, named after its discoverer. The pruritus or itching is typically
described in cycles (sometimes present, sometimes not).
The
lesions can appear anywhere on the body, including mucous membranes
and appendages such as nails and scalp.
On the oral mucosa,
they appear as
whitish striations
on the palate and the surface of the tongue. They are generally
painful, including the genital region.
It can occur in both
men and women, and usually in adults, but has also been described in
adolescents and children.
THE DISEASE IS NOT CONTAGIOUS.
After many years the advance of the science had been able to decipher
numerous events about the LICHEN PLANUS, they are:
CLINICAL TYPES OF LICHEN PLANUS:
-----------------------------------------------------
1.) Actinic.
2.) Annulare
3.) Bullous.
4.) Classic.
5.) Erythematosus.
6.) Exfoliative.
7.) familial
8.) Guttate.
9.) Hypertrophic.
10.) "invisible"
11.) Lineal.
12.) Muco-membranous (genital, esophagus)
13.) Nail.
14.) Oral.
15.) Penphigoides.
16.) Perforanting.
17.) Pigmentosus.
18.) Planopilaris.
19.) Ulcerative.
20.) Zosteriform.
The oral one has 6 types: Reticulated, atrophic, papular, plaquelike,
erosive and bullous.
ASSOCIATE DISEASES:
------------------------------------
Numerous illnesses associated with LICHEN PLANUS have been described,
among them:
A.) MALIGNANCIES:
-------------------------------
1.) Stomach Cancer.
2.) Lymphoma.
3.) Neuroblastoma.
4.) Adenoma of the pituitary.
5.) Fibrohistiocytoma.
6.) IGA Kappa monoclonal paraproteinemia.
7.) Craniopharyngioma
8.) Pararrenal malignancy.
9.) Sarcoma.
B.) GASTROINTESTINAL AND ENDOCRINE DISEASE
-------------------------------------------------------------------------
1.) Primary biliar cirrhosis (PBC).
2.) Chronic active hepatitis (CAH).
3.) Ulcerative colitis.
4.) Diabetes mellitus.
5.) Abnormalities in the liver function (enzymes).
C.) AUTOIMMUNE DISEASES:
-------------------------------------------------------------------------
1.) Alopecia Areata.
2.) Dermatomyositis.
3.) Dermatitis Herpetiformis.
4.) Hashimoto's Thyroiditis.
5.) Keratoconjunctivitis sicca and xerostomia.
6.) Morphea.
7.) Myasthenia Gravis.
8.) Penphigus foliaceus.
9.) Penphigus Vulgaris.
10.) Pernicious anemia.
11.) systemic sclerosis.
12.) Thymoma.
13.) Vitiligo.
Also the LICHEN PLANUS had been associated to the use of numerous drugs
and substances:
DRUG ASSOCIATED WITH LICHEN PLANUS:
--------------------------------------------
Numerous drugs have been involved in the appearance of LICHEN PLANUS,
called LP-like reactions, among them:
A.) ANTIHYPERTENSIVE:
Captopril, chlorothiazide, Enalapril, Hydroclorothiazide, Labetolol,
Methyldopa, practolol, propranolol, pironolactone.
B.) ANTIBIOTICS:
Demeclocycline, Ethambutol, Griseofulvin, Ketoconazole, Levamisole,
Para-amino-salicylic acid, streptomycin, teracycline.
C.) NON STEROIDAL ANTIINFLAMMATORY DRUGS:
Naproxen, Indomethacin, Feclofenac, Diflunisal, Flurbiprofen,
Benoxaprofen, acetylsalicylic acid.
D: ANTIMALARIALS:
Chloroquine, Quinacrine, Quinidine, Quinine, hydroxychloroquine.
E.) PSYCHOTROPIC /NEUROLOGIC:
Carbamazepine, Levomepromazine, Metopromazine, Olanzapine.
F.) FILMS DEVELOPING AGENTS:
4-Amino-N-diethyl-analine sulfate (TTS), CD2, CD3,
p-Isopropylamino-diphenylamine (IPPD).
G.) SULFONYLUREAS:
Chlorpropamide, Tolazamide, Tolbutamide.
H.) MISCELLANEOUS:
Allopurinol, anphenazole, arsenic, cinnarizine, gold, methycran, Musk
ambrette, penicillamine, probenecid, phyrimethamine,
mercaptopropionylglycine, pyrithioxin, radiocontrast media,
trihexyphenidyl, interferon-alpha-N1.
... and probably exist other but that are not in this list.
Genetically an association of the HLA antigens and THE LICHEN PLANUS it
has been observed, also the emotional STRESS is a causing factor, the
consumption of TOBACCO has also been related to the same one, and the
infections.
THERAPEUTIC ALTERNATIVES:
-------------------------------------------
It has been used several proposals for the treatment of the LICHEN
PLANUS, among them they highlight:
1.) RETINOIDS: Isotretinoin, Etretinat, Acitretin, Temarotene.
2.) GRISEOFULVIN.
3.) CYCLOSPORINE A.
4.) ANTIBIOTICS: Penicillin, Isoniazid, Aureomycin,
Trimethoprim-Sulfamethoxazole, tetracycline.
5.) ANTIPARASITE DRUGS: Metronidazole, Levamisole.
6.) DAPSONE and THALIDOMIDE
7.) ANTIMALARIALS: Phenytoin.
8.) RADIOTHERAPY.
9.) ANTIMETABOLITES: Cyclophosphamide, metotrexate.
10.) CORTICOSTEROIDS: Clobetasol and triamcinolone acetonide.
11.) PSYCHIATRIC MEDICATION: Sulpiride.
12.) AZATHIOPRINE.
13.) PUVA: psoralens plus UVA radiation.
14.) SURGERY.
15.) OLD THERAPIES INCLUDE: Systemic Mercury, nicotinic acid, Bismuth,
vitamins, intravenous calcium, and arsenicals.
OTHERS NEW ALTERNATIVES OF TREATMENT:
-----------------------------------------------------------------
1.) RECOMBINANT PLETELET-DERIVED GROWHT FACTOR AND INMUNOSUPRESION.
2.) glycyrrhizin (LICORICE), GRASS OF CHINESE ORIGIN.
3.) TACROLIMUS AND PIMECROLIMUS TOPIC.
4.) HEPARIN. (ENOXAPARIN)
5.) INTERFERON ALFA - 2b
6.) EXTRACORPOREAL PHOTOCHEMOTHERAPY.
7.) MOFETIL MYCOPHENOLATE
8.) Amlexanox, formulated in a 5% paste
9.) DIODE LASER (Low level laser therapy)
10.) BARICITINIB (Janus Kinase JAK 1 and 2 Inhibitor)
11.)
TOFACITINIB (Janus Kinase JAK 1 and 3 Inhibitor)
12.) RUXOLITINIB
(Topical Janus Kinase 1 and 2 Inhibitor).
13. DEUCRACITINIB (It is
a selective inhibitor of tyrosine kinase 2 (TYK2, currently being
studied in Lichen planus).
14. UPACITINIB (Janus Kinase JAK 1
Inhibitor).
Based on all these discoveries we could CLASSIFY THE LICHEN PLANUS on
their origin IN SEVEN (7) VARIANTS.
1.) ASSOCIATED TO HEPATIC DISEASES.
2.) ASSOCIATED TO OTHER NON HEPATIC DISEASES.
3.) INDUCED BY DRUGS AND POLLUTANTS.
4.) IDIOPATHIC.
5.) CUTANEOUS MARKER OF MALIGNANCY.
6.) GENETIC (HLA ANTIGENS)
7.) INDUCED BY HEPATITIS B VACCINE
Erasmus Wilson probably NEVER THOUGHT the great relationship that has
been discovered between the LICHEN PLANUS AND HEPATIC or
ABNORMALITIES in the HEPATIC FUNCTION, And even more the appearance of
the same after the vaccination against another disease (HEPATITIS
B).
in these 81 references the facts ... in the attach clasical lichen
planus, lineal, oral and chest manifestations !
===============================================================
REFERENCIAS BIBLIOGRÁFICAS / BIBLIOGRAPHICAL REFERENCES
===============================================================
A.- Updates In Therapeutics for Lichen Planus Pigmentosus
(2022). B.- Review of Nail Lichen Planus: Epidemiology, Pathogenesis, Diagnosis,
and Treatment (2021).
C.- Oral Lichen Planus: An Update on Diagnosis and Management (2024). D.- Treatment of Oral Erosive Lichen Planus With Upadacitinib (2022). E.- [Treatment of oral lichen planus-a review] (2025).
F.- Erosive Lichen Planus (2017).
G.- Coexistence of oral lichen planus and vulvar lichen sclerosus (2025).
H.- Lichen Planus: What Is New in Diagnosis and Treatment? (2024).
I.- Hypertrophic Lichen Planus: An Up-to-Date Review and Differential
Diagnosis (2024).
J.- Distinct Variations in Gene Expression and Cell Composition Across
Lichen Planus Subtypes 2024).
K.- Successful Treatment of Erosive Lichen Planus With Tofacitinib: A
Case Series and Review of the Literature 2024).
L.- JAK inhibitors in lichen planus: a review of pathogenesis and
treatments (2022).
M.- Successful treatment of childhood lichen planus with upadacitinib
(2024).
N.- Successful treatment of erosive lichen planus with Upadacitinib
complicated by oral squamous cell carcinoma 2023).
O.- TYK2 inhibition with deucravacitinib ameliorates erosive oral
lichen planus (2024).
P.- Rapid response of lichen planus to baricitinib associated with
suppression of cytotoxic CXCL13+CD8+ T cells (2024).
Q.- Recalcitrant multi-variant lichen planus successfully treated with
oral baricitinib and topical ruxolitinib cream (2024).
R.- Mycophenolate mofetil and lichen planopilaris: systematic review
and meta-analysis 2022).
S.- Assessment of 5% Amlexanox, 0.1% Triamcinolone Acetonide and 0.03%
Tacrolimus in the Management of Oral Lichen Planus (2023).
T. Bidirectional Association between Lichen Planus and Hepatitis C-An
Update Systematic Review and Meta-Analysis 2023).
W.- Survey of Medical Referral by Japanese Dentists for Patients With
Hepatitis B, Hepatitis C, and Lichen Planus (2024).
=============================================================== 1.) Lichen planus involving the esophagus.
2.) Hepatitis C virus infection prevalence in lichen planus: examination of
lesional and normal skin of hepatitis C virus-infected patients with lichen
planus for the presence of hepatitis C virus RNA.
3.) [Lichen planus and hepatitis C virus. Apropos of 5 new cases] TO: Lichen
plan et virus de l'hepatite C. A propos de 5 nouveaux cas.
4.) Lichen planus occurring after hepatitis B vaccination: a new case.
5.) A case of oral lichen planus with chronic hepatitis C successfully
treated by glycyrrhizin (LICORICE)
6.) Nail lichen planus in children: clinical features, response to
treatment, and long-term follow-up.
7.) Azathioprine for the treatment of severe erosive oral and generalized
lichen planus.
8.) Ulcerative lichen planus: a case responding to recombinant
platelet-derived growth factor BB and immunosuppression.
9.) [Study on regulatory effect of composite taixian tablet on immune
function of red blood cell in patients with oral lichen planus]
10.) Topical tacrolimus and pimecrolimus: future directions.
11.) Tacrolimus clinical studies for atopic dermatitis and other
conditions.
12.) Low-dose low-molecular-weight heparin (enoxaparin) is beneficial
inlichen planus: a preliminary report
13.) Low-dose low-molecular-weight heparin in lichen planus
14.) Management of recalcitrant ulcerative oral lichen planus with topical
tacrolimus.
15.) Topical tacrolimus in the treatment of symptomatic oral lichen planus:
a series of 13 patients.
16.) Mast cell degranulation and the role of T cell RANTES in oral lichen
planus.
17.) Levamisole and/or Chinese medicinal herbs can modulate the serum level
of squamous cell carcinoma associated antigen in patients with erosive oral
lichen planus.
18.) Dramatic response to levamisole and low-dose prednisolone in 23
patients with oral lichen planus: a 6-year prospective follow-up study.
19.) Successful treatment of generalized lichen planus with recombinant
interferon alfa-2b.
20.) [Prevalence of oral lichen planus and oral leukoplakia in 112 patients
with oral squamous cell carcinoma]
21.) Dental metal allergy in patients with oral, cutaneous, and genital
lichenoid reactions.
22.) [Cellular immune alterations in fifty-two patients with oral lichen
planus.]
23.) Isolated lichen planus of the toe nails treated with oral
prednisolone.
24.) Lichen planus-like eruption following autologous bone marrow
transplantation for chronic myeloid leukaemia.
25.) Immune mechanisms in oral lichen planus.
26.) Cyclosporin A in the treatment of lichen planus.
27.) Oral metronidazole treatment of lichen planus.
28.)Idiopathic lichen planus: treatment with metronidazole.
29.) Intestinal amebiasis, lichen planus, and treatment with
metronidazole.
30.) Urinary tract infection as a cause of lichen planus: metronidazole
therapy.
31.) [Metronidazole treatment of the erosive ulcerative form of lichen ruber
planus of the oral mucosa]
32.) Clinical and pathological characteristics of oral lichen planus in
hepatitis C-positive and -negative patients.
33.) High prevalence of anticardiolipin antibodies in patients with
HCV-associated oral lichen planus.
34.) The clinical features, malignant potential, and systemic associations
of oral lichen planus: a study of 723 patients.
35.) Management of oral lichen planus.
36.) Lichen planus occurring after hepatitis B vaccination: a new case.
37.) TT virus detection in oral lichen planus lesions.
38.) Lichenoid eruption following hepatitis B vaccination: first North
American case report.
39.) Increased frequency of HLA-DR6 allele in Italian patients with
hepatitis C virus-associated oral lichen planus.
40.) Extrahepatic manifestations of chronic viral hepatitis.
41.) Prevalence of hepatitis C virus in patients with lichen planus of the
oral cavity and chronic liver disease.
42.) Histopathological and immunohistochemical study of oral lichen
planus-associated HCV infection.
43.) Previous tuberculosis, hepatitis C virus and lichen planus. A report of
10 cases, a causal or casual link?
44.) [Skin diseases and hepatitis virus C infection]
45.) [Extrahepatic manifestations of hepatitis C virus infection]
46.) Detection of hepatitis C virus RNA in oral lichen planus and oral
cancer tissues.
46.) Oral lichenoid lesions after hepatitis B vaccination.
47.) [The extrahepatic manifestations in hepatitis C virus (HCV)
infection]
48.) Association of HLA-te22 antigen with anti-nuclear antibodies in Chinese
patients with erosive oral lichen planus.
49.) Treatment of autoimmune and extra-hepatic manifestations of HCV
infection.
50.) Lichen planus, erythema nodosum, and erythema multiforme in a patient
with chronic hepatitis C.
51.) [Clinical considerations and statistical analysis on 100 patients with
oral lichen planus]
52.) Lichen planus in children: a possible complication of hepatitis B
vaccines.
53.) Lichen planus actinicus treated with acitretin and topical
corticosteroids.
54.) Alendronate-induced lichen planus.
55.) Hepatitis C virus and lichen planus in Nigerians: any relationship?
56.) Helicobacter pylori Infection in Skin Diseases: A Critical
Appraisal.
57.) Presence of lichen planus during a course of interferon alpha-2a
therapy for a viral chronic C hepatitis.
58.) Lichen planus-like eruption following autologous bone marrow
transplantation for chronic myeloid leukaemia.
59.) [Clinical evaluation in oral lichen planus with chronic hepatitis C:
the role of interferon treatment]
60.) Oral lichen planus induced by interferon-alpha-N1 in a patient with
hepatitis C.
61.) Treatment of lichen planus. An evidence-based medicine analysis of
efficacy.
62.) Successful Treatment of Resistant Hypertrophic and Bullous Lichen
Planus With Mycophenolate Mofetil
63.) Liver abnormalities in patient with lichen planus.
64.) Lichen planus.
65.) Evaluation of Hepatitis B Vaccination among
Lichen Planus Patients.
66.) Lichen planus associated with hepatitis C
virus: no viral transcripts are found in the lichen planus, and effective
therapy for hepatitis C virus does not clear lichen planus.
67.) Lichen
planus secondary to hepatitis B vaccination.
68.) A clinical evaluation
of the efficacy of photodynamic therapy in the treatment of erosive oral
lichen planus: A case series.
69.) Possible alternative therapies for
oral lichen planus cases refractory to steroid therapies.
70). Novel
therapies for oral lichen planus.
71.) The effect of diode laser and
topical steroid on serum level of TNF-alpha in oral lichen planus
patients.
===============================================================